Marten Transport, Ltd (NASDAQ:MRTN) – Stock analysts at KeyCorp reduced their FY2020 earnings per share (EPS) estimates for shares of Marten Transport in a research report issued on Tuesday, June 18th, Zacks Investment Research reports. KeyCorp analyst T. Fowler now expects that the transportation company will earn $1.15 per share for the year, down from their prior forecast of $1.20.
Kraken Robotics Inc (CVE:PNG) – Equities research analysts at Clarus Securities issued their FY2019 EPS estimates for Kraken Robotics in a report released on Thursday, June 13th, according to Zacks Investment Research. Clarus Securities analyst J. Mackay anticipates that the company will earn $0.01 per share for the year.
Members of Britain’s Conservative Party have started receiving their postal ballots in the contest to become the country’s next prime minister, amid concern that some people have been sent more than one voting paper.
The US state of Alaska, part of which lies inside the Arctic Circle, is sweltering under a heatwave, with record temperatures recorded in several areas, including its largest city.
Turkey’s president has fired the central bank governor amid the country’s economic downturn.
India’s government has proposed heavy investments in infrastructure, the digital economy and job creation to lift a sluggish economy burdened with a 45-year-high unemployment rate.
The UK’s productivity puzzle is costing private sector workers an estimated £5,000 a year on average in lost income, a top statistician has said.
Jaguar Land Rover (JLR) is investing hundreds of millions of pounds to build a range of electric vehicles at its Castle Bromwich plant in Birmingham.
The US labour market boomed in June, creating many more jobs than expected, according to the latest report from the Bureau of Labor Statistics.
Depending on who you speak to, Le Freeport is a high-security storage facility or a money-laundering risk
Weekly Market Review – May 18, 2024
Gain Therapeutics’ clinical Parkinson’s drug restores motor function in mice
Eli Lilly axes next-generation, resistance-busting RET inhibitor
What’s behind the rise of colorectal cancer in younger adults? Bacteria may have the answer
Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks
Dexcom adds upgraded One+ glucose monitoring system to European slate
Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026
Kyverna raises IPO expectations by $100M, now eyeing almost $300M for latest biotech listing of 2024
After Incyte’s commercial buy, Novartis shells out €2.7B for cancer specialist MorphoSys
